









Markets
/
Stocks
/
nasdaq-kmda
/

Kamada Ltd

KMDA

6.955USD

+0.055+0.80%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

399.95MMarket Cap

21.04P/E TTM



Kamada Ltd

6.955

+0.055+0.80%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

56 / 175

Overall Ranking

158 / 4721

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Buy

Current Rating

16.000

Target Price

+131.88%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 24.44% year-on-year.

Undervalued

The company’s latest PE is 20.98, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 32.16M shares, decreasing 3.49% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 832.00K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-18

The company's current financial score is 9.08, which is higher than the Pharmaceuticals industry's average of 7.84. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 44.75M, representing a year-over-year increase of 5.37%, while its net profit experienced a year-over-year increase of 66.65%.

Score

Industry at a Glance

Previous score

9.08

Change



Financials

8.85

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.46

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

8.09

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 1.80, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is 20.81, which is 28.61% below the recent high of 26.76 and -10.63% above the recent low of 23.02.

Score

Industry at a Glance

Previous score

1.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 56/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

The company’s current earnings forecast score is 8.67, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for Kamada Ltd is 15.00, with a high of 20.00 and a low of 13.00.

Score

Industry at a Glance

Previous score

8.67

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Buy

Current Rating

16.000

Target Price

+131.88%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Kamada Ltd

KMDA

Biogen Inc

BIIB

Amgen Inc

AMGN

Alnylam Pharmaceuticals Inc

ALNY

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 6.51, which is lower than the Pharmaceuticals industry's average of 6.64. Sideways: Currently, the stock price is trading between the resistance level at 7.29 and the support level at 6.66, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.51

Change

0.15

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.006

Sell

RSI(14)

44.777

Neutral

STOCH(KDJ)(9,3,3)

24.093

Neutral

ATR(14)

0.204

High Vlolatility

CCI(14)

-77.041

Neutral

Williams %R

75.397

Sell

TRIX(12,20)

-0.148

Sell

StochRSI(14)

77.767

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

6.947

Buy

MA10

7.040

Sell

MA20

7.042

Sell

MA50

7.280

Sell

MA100

7.174

Sell

MA200

6.945

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 5.00, which is lower than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 55.76%, representing a quarter-over-quarter increase of 0.62%. The largest institutional shareholder is James Simons, holding a total of 832.00K shares, representing 1.44% of shares outstanding, with 0.32% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

First Israel Mezzanine Investors Ltd.

22.08M

Gov Financial Holdings, Ltd.

2.80M

-1.96%

Phoenix Investment and Finances Ltd

1.65M

-9.71%

Renaissance Technologies LLC

Star Investors

808.30K

-2.84%

Recanati (Leon Yehuda)

631.14K

Wells Fargo Advisors

608.59K

-3.50%

Tsur (David)

607.93K

Dimensional Fund Advisors, L.P.

412.01K

+2.31%

More Investment House Ltd.

330.35K

-33.79%

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 5.18, which is higher than the Pharmaceuticals industry's average of 4.07. The company's beta value is 0.86. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.